Randomized controlled trials (RCTs) are the gold standard for inferring causal differences in treatment effects, but because the study of HF outcomes requires a very long follow-up time and insulin is a generic medication, there is little incentive for private sponsors to support RCTs comparing insulin to patent-protected agents. Here, INS is linked to hydrops fetalis.